Complete radiological response to first-line regorafenib in a patient with abdominal relapse of BRAF V600E mutated GIST

Sabrina Rossi, Daniela Gasparotto, Rosalba Miceli, Luisa Toffolatti, Giovanna Gallina, Enrico Scaramel, Alessandra Marzotto, Elena Boscato, Luca Messerini, Italo Bearzi, Guido Mazzoleni, Carlo Capella, Gianluigi Arrigoni, Aurelio Sonzogni, Angelo Sidoni, Luigi Mariani, Paola Amore, Alessandro Gronchi, Paolo G. Casali, Roberta Maestro, Angelo P. Dei Tos, KIT, PDGFRA, and BRAF Mutational Spectrum Impacts on the Natural History of Imatinib-naive Localized GIST The American Journal of Surgical Pathology. ,vol. 39, pp. 922- 930 ,(2015) , 10.1097/PAS.0000000000000418

Axel Grothey, Yiyi Yan, Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. OncoTargets and Therapy. ,vol. 8, pp. 2949- 2957 ,(2015) , 10.2147/OTT.S79145

Scott M. Wilhelm, Jacques Dumas, Lila Adnane, Mark Lynch, Christopher A. Carter, Gunnar Schütz, Karl-Heinz Thierauch, Dieter Zopf, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity International Journal of Cancer. ,vol. 129, pp. 245- 255 ,(2011) , 10.1002/IJC.25864

Isabelle Hostein, Nicolas Faur, Charlotte Primois, Frédérique Boury, Jérome Denard, Jean-François Emile, Pierre-Paul Bringuier, Jean-Yves Scoazec, Jean-Michel Coindre, BRAF Mutation Status in Gastrointestinal Stromal Tumors American Journal of Clinical Pathology. ,vol. 133, pp. 141- 148 ,(2010) , 10.1309/AJCPPCKGA2QGBJ1R

Margherita Nannini, Guido Biasco, Annalisa Astolfi, Maria A Pantaleo, An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST) Journal of Medical Genetics. ,vol. 50, pp. 653- 661 ,(2013) , 10.1136/JMEDGENET-2013-101695

Sebastian Huss, Sandra Elges, Marcel Trautmann, Jan Sperveslage, Wolfgang Hartmann, Eva Wardelmann, Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy. Expert Review of Anticancer Therapy. ,vol. 15, pp. 623- 628 ,(2015) , 10.1586/14737140.2015.1032941

A Agaimy, L M Terracciano, S Dirnhofer, L Tornillo, A Foerster, A Hartmann, M P Bihl, V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours Journal of Clinical Pathology. ,vol. 62, pp. 613- 616 ,(2009) , 10.1136/JCP.2009.064550

Marc Daniels, Irene Lurkin, Roland Pauli, Erhard Erbstößer, Uwe Hildebrandt, Karsten Hellwig, Uwe Zschille, Petra Lüders, Gabriele Krüger, Jürgen Knolle, Bernd Stengel, Friedrich Prall, Kay Hertel, Hartmut Lobeck, Brigitte Popp, Franz Theissig, Peter Wünsch, Ellen Zwarthoff, Abbas Agaimy, Regine Schneider-Stock, Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST) Cancer Letters. ,vol. 312, pp. 43- 54 ,(2011) , 10.1016/J.CANLET.2011.07.029

Narasimhan P. Agaram, Grace C. Wong, Tianhua Guo, Robert G. Maki, Samuel Singer, Ronald P. DeMatteo, Peter Besmer, Cristina R. Antonescu, Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors Genes, Chromosomes and Cancer. ,vol. 47, pp. 853- 859 ,(2008) , 10.1002/GCC.20589

George D Demetri, Peter Reichardt, Yoon-Koo Kang, Jean-Yves Blay, Piotr Rutkowski, Hans Gelderblom, Peter Hohenberger, Michael Leahy, Margaret von Mehren, Heikki Joensuu, Giuseppe Badalamenti, Martin Blackstein, Axel Le Cesne, Patrick Schöffski, Robert G Maki, Sebastian Bauer, Binh Bui Nguyen, Jianming Xu, Toshirou Nishida, John Chung, Christian Kappeler, Iris Kuss, Dirk Laurent, Paolo G Casali, Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial The Lancet. ,vol. 381, pp. 295- 302 ,(2013) , 10.1016/S0140-6736(12)61857-1